ABSTRACT
BACKGROUND
The remarkable efficacy of immunologic interventions in controlling certain cancers has prompted renewed interest in the potential of cancer vaccines as one arm of the immunologic approach. A focus of this interest has been identifying more effective adjuvants, which, among other properties, would attract more immune cells to the site of vaccine exposure. However, only 5-10% of inflammatory cells attracted to vaccination sites by adjuvants actually play a role in the initiation of the immune response 1 . To more efficiently direct vaccine antigen to the dendritic cells critical to the initiation of the adaptive immune response, we have been studying the effect of genetically fusing a vaccine antigen to the chemokine macrophage inflammatory protein 3 alpha (MIP3α), also known as chemokine (C-C motif) ligand 20 (CCL20), which targets the vaccine antigen to the C-C chemokine receptor type 6 (CCR6) on immature dendritic cells (iDC) 2, 3 .
The simple addition of this small molecule to the vaccine construct has been shown to enhance immunogenicity and efficacy over antigen-only vaccinations in melanoma 2,4,5 , lymphoma 6 , and malaria model systems 7, 8 . A therapeutic melanoma DNA vaccine in which
MIP3α is fused to amino acids 25-235 of the human melanoma-associated antigen gp100 proved superior compared to vaccines comprised of defective MIP3α (D-MIP3α) fused to gp100 or MIP3α fused to an irrelevant antigen 4 .
Therapeutic cancer vaccines have historically failed as a monotherapy against established and progressing tumors, but recent studies have highlighted the potential of novel vaccine platforms to be effective when used in combination with other cancer therapies, especially other immunotherapies (reviewed in 9 ). To address immunosuppressive factors in the tumor microenvironment, we examined the effect in the mouse melanoma model of neutralizing IL-10 used in combination with the MIP3α-gp100 vaccine 5 . This approach generated significant, but moderate improvement in survival. Importantly the observed improvement in survival was shown to be mediated by enhanced type 1 interferon activity 5 .
In the current study, we have explored the potential importance of Type I interferons in enhancing the effect of the vaccine-generated immune response. For this purpose, we have added to the therapeutic regimen direct administration of recombinant IFN-α, the type I IFNstimulating adjuvant CpG, and an inhibitor of methyl transferase activity, as DNA methylation has been shown to attenuate the activity of interferon-stimulated genes (ISG's) [10] [11] [12] . Also because of evidence from studies supporting the use of multiple antigens in cancer vaccines [13] [14] [15] , we have added the melanoma antigen tyrosinase-related protein 2 (Trp2) to our original gp100 vaccine construct. The results of our study indicate that this combined regimen effectively doubles survival time compared to the negative control in this melanoma model system.
METHODS

Animals and Tumor Model
5-6 week old female C57BL/6 (H-2b) mice were purchased from Charles River Laboratories Mice were kept in survival studies until one of the following occurred: mouse death, tumor diameter eclipsing 20mm, significant lethargy, or extensive tumor necrosis resulting in excessive bleeding.
Plasmid Design
The original plasmid encoded the MIP3α-hgp100 fusion sequence, where the antigen includes amino acids 25-235 of human gp100, as described 4 
RNA Extraction and qRT-PCR
Mice were sacrificed and portions of tumor weighing less than 100mg were harvested. Tumor 
Statistics and Data
Tumor size, immunologic, RT-PCR, and flow cytometric analyses were statistically tested by 
RESULTS
Addition of Trp-2 to vaccine
Previous work from our laboratory has shown that the fusion of MIP3α to gp100
enhanced the immunogenicity and efficacy of a DNA vaccine 4 . In the current experiment, a 100 amino acid region of the melanoma-associated antigen tyrosinase-related protein 2 (Trp2) was added to the construct to create a two-antigen vaccine referred to as MIP3α-GpTrp or MGpTrp.
The region of Trp2 includes the known class-I immunodominant epitope Trp2180-188 16 . Figure 1A shows a diagram of the expressed constructs used in this study. Enhancing the response with CpG adjuvant, IFNα, and Aza
Previous work from our laboratory provided evidence that neutralizing IL-10 at the tumor site could enhance therapeutic efficacy in a type-1 interferon pathway dependent manner 5 . It has also been shown that Aza can enhance the efficacy of IFNα therapy 10 , and that CpG oligonucleotides can enhance vaccine efficacy by mechanisms that include type-I interferon activity [10] [11] [12] . With this focus on type 1 interferon, a therapeutic protocol was designed with CpG adjuvanted MIP3α-GpTrp used in combination with Aza and a high-low dose series of IFNα treatments as outlined in Figure 2A . Henceforth, 'vaccine' will refer to the MGpTrp construct adjuvanted by CpG.
On day 19 post tumor challenge, the tumor sizes of seven groups were analyzed, comparing the relative efficacies of all combinations of vaccine, Aza, and IFNα ( Figure 2B ).
PBS only mice were excluded from analysis due to mice already reaching euthanasia thresholds.
Judging by tumor growth in Figure 2C , the negative PBS vaccinated mice had similar tumor growth and size as the PBS vaccinated mice given Aza. Therefore, PBS+Aza mice are treated as the negative control comparator for figure 2B. Tumor growth over time up through day 21 post challenge was also monitored and tested ( Figure 2C ). In addition, mouse survival was assessed ( Figure 2D ). In all three of these figures, a similar pattern is seen. Interferon stimulated gene expression While IFNα and Aza are known to influence transcription of many genes [10] [11] [12] 17 , of particular interest for these studies was a report indicating that Aza enhances upregulation of interferon stimulated genes such as Mx1 10 . To assess the transcription levels of Mx1 as a marker for such upregulation, two different therapeutic protocols were utilized. First, to assess transcription levels early in the therapy, a modified schedule was utilized as outlined in Figure   3A . For this schedule, the initiation of treatment was delayed until day 8 post challenge, but the intervals between treatments were left unchanged. This approach ensured tumors of adequate size for analysis at a timepoint 3 days after the first full round of treatment. Second, a late timepoint analysis utilized the standard schedule but with tumor harvested for analysis one week after the final vaccination ( Figure 3A) . The overall TIL fraction was also analyzed. Figure 5C shows that by percentage there was no difference between groups with regards to CD3+CD4+ TILs. In contrast, the percentage of TILs that are CD3+CD8+ were markedly different ( Figure 5D ). Average percent levels of CD3+CD8+ TILs in vaccine+IFNα+Aza were elevated compared to all other groups.
Vaccine+Aza and vaccine+IFNα groups had higher CD3+CD8+ TIL percentage than the IFNα+Aza group (p<0.01), but were not substantially higher than vaccine alone. Similar relationships are seen when estimating the total CD3+CD8+ TILs adjusted for tumor size ( Figure   5E ). Although not significantly higher as compared to vaccine+Aza by this measure, the vaccine+IFNα+Aza group has higher numbers of CD3+CD8+ TILs as compared to IFNα+Aza, vaccine alone, and vaccine+IFNα groups.
The correlations of tumor size and TIL percentage across groups were also analyzed. 
DISCUSSION
In this study, we first provided evidence that the addition of a second antigen in the vaccine improved mouse survival. Vaccines with multiple antigens run the risk of antigenic competition 18 . However, many studies show multi-epitope vaccines with enhanced efficacy correlating with vaccine antigenic valency 14, 15 , and in clinical trials, objective response rates of cancer vaccines were improved with multi-peptide strategies 13 . The MIP3α-antigen vaccine platform had not yet been tested with multiple protein targets. Tyrosinase-related protein 2 (Trp2) is a melanoma-associated antigen similar to gp100 in that it has been successful in developing vaccine-derived anti-tumor immunity in preclinical models, and it has a known immunogenic MHC-I epitope (amino acids 180-188) [19] [20] [21] [22] . Additionally, use of a peptide of longer length has been shown to be enhance efficacy 23 , and therefore a 100 amino acid region of Trp2, including 180-188, was added to the MIP3α-gp100 construct to form a MIP3α-Gp100-Trp2 vaccine. The data showed that MIP3α continued to enhance the efficacy of a multi-epitope vaccine and that inclusion of both Gp100 and Trp2 antigenic regions together provided superior survival over either single antigen vaccine. The additive increase in efficacy shows that this platform is amenable to multi-epitope strategies. The addition of more tumor associated antigens and/or neoantigens as well as the relative immunogenicity of each antigen will be the subject of future studies.
We have shown previously that neutralizing IL-10 modestly enhanced vaccine therapeutic efficacy, an effect that was mediated through Type 1 interferon pathways 5 . IFNα is known to provide direct therapeutic efficacy via its ability to modulate anti-tumor immunity 24 , and it has also been studied as a potential vaccine adjuvant 25 However, data from our studies did not support a finding that Aza was acting by enhancing or extending expression of ISG's. We observe upregulated Mx1 expression when
IFNα is added to the vaccine therapy, but that effect was not further enhanced by Aza. The difference from the Lucarini study might be due to a difference between our two experimental designs. They utilized five consecutive immunizations of 5x10 4 U of IFNα 10 , whereas our study utilized a series of one dose at 1x10 4 U followed by three doses of 1x10 3 U, a more clinically realistic schedule.
Beyond their potential effect on ISG's, the combination of Aza and type-I interferons in the B16F10 melanoma model has been reported to produce an increased percentage of CD8+ tumor infiltrating lymphocyteswith these findings. The overall CD8+ TIL infiltrate was enhanced. While the vaccine specific TILs were not selectively enhanced by percentage, the overall increase in TILs led to more vaccine-specific CD8+ TILs by number. A likely mechanism of the enhanced CD8+TIL infiltration could be due to increased intratumoral production of proinflammatory cytokines and chemokines and/or reduction of regulatory immune cells 10 . This mechanism will be further analyzed in future studies. Importantly, mice vaccinated without additional treatment developed a strong CD8+ T-cell response early that was lost later, whereas the groups including vaccine and IFNα still maintained a significant vaccine-specific CD8+ T-cell response at the later time point.
CONCLUSION
The MIP3α-antigen vaccine platform has shown promise as a unique approach to cancer vaccination. Our results show that the platform is amenable to multi-antigen vaccine designs.
Further, the vaccine efficacy can be greatly enhanced by the addition of agents affecting the type-I interferon pathway. The data indicate that the synergy seen in this study is due to the 
LIST OF ABBREVIATIONS
• Aza: 5-Aza-2'-Deoxycytdine
• IFNα: Interferon alpha
• TIL: Tumor Infiltrating Lymphocyte
• MIP-3α: Macrophage Inflammatory Protein-3 alpha
• MGp100: Vaccine fusing MIP-3α to antigenic region of Gp100
• Trp2: Tyrosinase-related protein 2
• MtTrp2: Vaccine fusing MIP-3α to antigenic region of Trp2
• MGpTrp2: Vaccine fusing MIP-3α to antigenic regions of Gp100 and Trp2
• i.p.: intra-peritoneal administration
• i.m.: Intra-muscular administration
• i.t.: Intra-tumoral administration
• qRT-PCR: quantitative reverse-transcriptase polymerase chain reaction
• CCL20: C-C motif ligand 20
• CCR6: C-C Receptor 6
• iDC: Immature Dendritic Cells
• D-MIP3α: Defective version of MIP3α
• IL-10: Interleukin 10
• ISG: Interferon Stimulated Gene Leukocytes were gated by forward and side scatter from overall cells and were then screened by doublet and live/dead discrimination. TILs were determined by CD3 positivity followed by 
